. 2012 Aug 2;13(4):1266–1275. doi: 10.1208/s12249-012-9828-x

Table V.

Effect of Concentration of Oxyresveratrol Microemulsion in Cutaneous HSV-1 Infection in Mice

Treatment^a	Mean time^b (days, mean ± SD)				% Mortality^c
Treatment^a	Score 2	Score 4	Score 6	Survival	% Mortality^c
Untreated control	5.81 ± 0.59	6.27 ± 0.53	7.18 ± 0.40	7.55 ± 0.79	100
ME base, ×5	6.29 ± 0.59	7.02 ± 0.95	7.62 ± 0.81	8.11 ± 0.76	100
ORME 10%, ×5	6.80 ± 0.82^d	7.10 ± 0.82^d	7.72 ± 0.51^d	7.92 ± 0.43^d	100
ORME 15%, ×5	7.06 ± 1.27^d	8.10 ± 1.16^d	>8.29 ± 0.95^d	>8.66 ± 0.98^d	70
ORME 20%, ×5	>8.30 ± 1.68^d	>8.64 ± 1.37^d	>9.07 ± 0.91^d	>9.30 ± 0.78^d	30^e
ORME 25%, ×5	>8.90 ± 1.51^d	>9.18 ± 1.11^d	>9.22 ± 1.03^d	>9.20 ± 1.0^d	40^e
ORME 30%, ×5	>9.34 ± 1.28^d	>9.40 ± 1.15^d	>9.48 ± 1.01^d	>9.50 ± 0.99^d	30^e
OR in Vaseline 30%, ×5	>7.84 ± 2.05^d	>8.27 ± 1.71^d	>8.69 ± 1.25^d	>9.02 ± 1.05^d	40^e
ACV 5%, ×5	>10^d	>10^d	>10^d	>10^d	0^e

OR oxyresveratrol, ME microemulsion, ORME oxyresveratrol-loaded ME, ACV acyclovir, SD standard deviation

^aORME was topically applied five times daily for 10 days after HSV-1 infection

^bMean time at which score 2, 4, and 6 or survival was observed after infection, determined from nine to ten mice in each group (the mean time with symbol > referred to a group of mice that had mice showing score 0 at day 10)

^cPercentage of mortality of mice tested, observed at day 10 after HSV-1 infection

^dMean time was significantly prolonged (p < 0.05 vs. untreated control)

^eMortality was significantly reduced (p < 0.05 vs. untreated control)